The findings of the FIGHT study, a randomized phase II trial evaluating the add-on effect of bemarituzumab to chemotherapy (FOLFOX) in the first-line treatment of FGFR2-positive advanced GC, were reported at ASCO 2021 [98]. This evidence concerns the gene FGFR2 and gastric cancer.